Filter Releases
 
Press Releases
Date Title and Summary View
Mar 9, 2015
WALTHAM, Mass., March 9, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers, today announced several updates for the investigational drug RA...
Mar 2, 2015
WALTHAM, Mass., March 2, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers, announced today the appointment of Tony Rosenberg to its Board ...
Feb 24, 2015
WALTHAM, Mass., Feb. 24, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that its Vice President, Business Development & Strategy, Geoffrey A. Swire, will present at the BIO-Europe Spring 2015 Paris Expo Conference on Tuesday, March 10, 2015 at 5:00 p.m. Central European Time at the Porte de Versailles, Paris, France. ...
Feb 24, 2015
WALTHAM, Mass., Feb. 24, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers, today announced that President and Chief Execu...
Feb 19, 2015
WALTHAM, Mass., Feb. 19, 2015 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its fourth quarter and full year 2014 financial results on Tuesday, March 10, 2015. In connection with the earnings release, Radius Health will host a conference call and live audio webcast at 7:30 a.m. ET on Tuesday, March 10, 201...
Feb 16, 2015
WALTHAM, Mass., Feb. 16, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) today announced that President and CEO, Robert Ward, will present at the 2015 RBC Capital Markets Global Healthcare Conference on February 25th at 11:00 a.m. EST at the New York Palace Hotel in New York City. The Company's presentation will be webcast live on th...
Feb 3, 2015
WALTHAM, Mass., Feb. 3, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that President and CEO, Robert Ward, will be presenting a company overview at the 17th Annual BIO CEO & Investor Conference on Monday, February 9th, 2015 at 5:00 p.m. Eastern Time at the Waldorf Astoria in New York City The company presentation wi...
Jan 29, 2015
WALTHAM, Mass., Jan. 29, 2015 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS), today announced that the Annual Meeting Steering Committee of ENDO 2015 has selected the company's recently completed Phase 3 ACTIVE study of abaloparatide-SC in post menopausal osteoporosis for the Late-Breaker oral presentations session at the International Society of ...
Jan 28, 2015
WALTHAM, Mass., Jan. 28, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) (the "Company"), a science-driven biopharmaceutical company focused on developing potential new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive cancers, today announced the closi...
Jan 22, 2015
WALTHAM, Mass., Jan. 22, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) (the "Company"), a science-driven biopharmaceutical company focused on developing potential new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediat...
Jan 20, 2015
WALTHAM, Mass., Jan. 20, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) (the "Company"), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive cancers, today announced that it is commenci...
Jan 12, 2015
...
Dec 21, 2014
Study Meets Primary Endpoint of Reducing the Percentage of Patients with Incident Vertebral Fracture and Also Meets Important Secondary Endpoints: Adverse Events Consistent with Previous Clinical ExperienceRadius Remains on Track for Completion of the Ongoing 6-Month ACTIVExtend Study and NDA Submission in the Second Half of 2015Radius' Investigati...
Dec 19, 2014
WALTHAM, Mass., Dec. 19, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company's Investigational New Drug (IND) application for its investigational drug RAD1901, a tissue-selective estrogen receptor degrader (SERD) being developed for potential use in met...
Dec 15, 2014
As a result of the annual re-ranking of the NASDAQ Biotechnology Index, NASDAQ announced today that Radius Health shares will be added to the index effective before the market open on Monday, December 22, 2014. WALTHAM, Mass., Dec. 15, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) will be added to the NASDAQ Biotechnology Index (Na...
= add release to Briefcase